Incyte reported strong Q3 revenue growth, mainly driven by Jakafi and Opzelura, with a 24% increase year-over-year. Find out ...
Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...
Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...
On Tuesday, Incyte Corporation (NASDAQ:INCY) reported third-quarter revenue of $1.14 billion, up 24% year over year, beating ...
Incyte Corp (INCY) reports a 24% revenue increase, driven by Jakafi and Opzelura, while navigating regulatory challenges and ...
With Jakafi's patent cliff looming, Incyte looks to 2025 launches to bulk up revenue by decade's end
Incyte’s blockbuster JAK inhibitor Jakafi has been driving the company’s sales for years now, with this quarter being no ...
Incyte delivered robust third-quarter revenue growth, surpassing expectations, despite increased operational costs.
Incyte (INCY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Andrew Berens ...
Q3 2024 Earnings Call Transcript October 29, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $1.07 ...
On Wednesday, Incyte Corp (INCY) stock saw a modest uptick, ending the day at $73.93 which represents a slight increase of $0.33 or 0.45% from the prior close of $73.6. The stock opened at $73.6 and ...
Citi raised the firm’s price target on Incyte (INCY) to $97 from $92 and keeps a Buy rating on the shares. Incyte reported Q3 results, ...
Shares of Incyte Co. (NASDAQ:INCY – Get Free Report) have been assigned an average recommendation of “Hold” from the twenty-one brokerages that are covering the company, Marketbeat.com reports. One ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback